Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLAT | P00750 | 1/20 | 0.41 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.36 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 7/20 | 0.36 |
| ▸ | PLG | P00747 | 1/20 | 0.36 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.35 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.35 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.35 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.35 |
| ▸ | PLK4 | O00444 | 1/20 | 0.34 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.34 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.34 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.34 |
| ▸ | PRKCG | P05129 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL18788541 | 0.98 | PLAT (0.40) | PLATBRD4KMT2AMEN1ALDH1A1 | |
| SCHEMBL18805137 | 0.88 | CALCA (0.37) | PLATBRD4KMT2AALDH1A1POLB | |
| Hydrochloric Acid SCHEMBL20522326 | 0.87 | CALCA (0.37) | PLATBRD4KMT2AMEN1ADORA2A | |
| SCHEMBL19772545 | 0.84 | JAK2 (0.40) | BRD4KMT2AMEN1KCNH2PLG | |
| SCHEMBL16247259 | 0.84 | CCNE1 (0.39) | PLATBRD4KMT2AMEN1KCNH2 | |
| SCHEMBL9894163 | 0.81 | BRD4 (0.34) | PLATBRD4KMT2AMEN1KCNH2 | |
| Hydrochloric Acid SCHEMBL16457105 | 0.80 | MEN1 (0.35) | PLATBRD4KMT2AMEN1KCNH2 | |
| SCHEMBL15942427 | 0.78 | MEN1 (0.42) | BRD4KMT2AMEN1HTR2CPLG | |
| Hydrochloric Acid SCHEMBL3259989 | 0.77 | MEN1 (0.45) | BRD4KMT2AMEN1HTR2CPLG | |
| Hydrochloric Acid SCHEMBL16992353 | 0.77 | MEN1 (0.45) | BRD4KMT2AMEN1HTR2CPLG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10166226-B2 | CGRP receptor antagonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2019-01-01 | — | — | US | disclosed |
| US-20180153876-A1 | CGRP Receptor Antagonists | NXERA PHARMA UK LIMITED (GB) | 2018-06-07 | — | — | US | disclosed |
| US-20180153876-A1 | CGRP Receptor Antagonists | NXERA PHARMA UK LIMITED (GB) | 2018-06-07 | — | — | US | disclosed |
| US-9925178-B2 | CGRP receptor antagonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2018-03-27 | — | — | US | disclosed |
| US-9925178-B2 | CGRP receptor antagonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2018-03-27 | — | — | US | disclosed |
| US-20170239236-A1 | CGRP Receptor Antagonists | NXERA PHARMA UK LIMITED (GB) | 2017-08-24 | — | — | US | disclosed |
| US-20170239236-A1 | CGRP Receptor Antagonists | NXERA PHARMA UK LIMITED (GB) | 2017-08-24 | — | — | US | disclosed |
| US-9688660-B2 | CGRP receptor antagonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2017-06-27 | — | — | US | disclosed |
| US-9688660-B2 | CGRP receptor antagonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2017-06-27 | — | — | US | disclosed |
| US-20170121311-A1 | CGRP RECEPTOR ANTAGONISTS | NXERA PHARMA UK LIMITED (GB) | 2017-05-04 | — | — | US | disclosed |
| WO-2017072723-A1 | CGRP RECEPTOR ANTAGONISTS | HEPTARES THERAPEUTICS LIMITED (GB) | 2017-05-04 | — | — | WO | disclosed |
| US-20170121311-A1 | CGRP RECEPTOR ANTAGONISTS | NXERA PHARMA UK LIMITED (GB) | 2017-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180153876-A1 | CGRP Receptor Antagonists | CALCRL, CNR1, GALR1 | PLAT 2792/4885BRD4 1235/4885KMT2A 4508/4885 |
| US-20170239236-A1 | CGRP Receptor Antagonists | CALCRL, CNR1, GALR1 | PLAT 2792/4885BRD4 1235/4885KMT2A 4508/4885 |
| US-20170121311-A1 | CGRP RECEPTOR ANTAGONISTS | CALCRL, CNR1, GALR1 | PLAT 2792/4885BRD4 1235/4885KMT2A 4508/4885 |
| US-10166226-B2 | CGRP receptor antagonists | CALCRL, CNR1, GALR1 | PLAT 2792/4885BRD4 1235/4885KMT2A 4508/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.